Bajetta et al.(44. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di BM. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13:299-307.)
|
274 |
EAP/FL |
52% vs 48% (5y) |
0,93 (0.65 – 1.34) |
49% vs 44% (5y) |
0.83 (0.59 – 1.17) |
Nashimoto et al.(4141. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S and Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21:2282-7.)
|
252 |
MFC/F |
91.2% vs 86.1% (5y) |
- |
88.8% vs 83.7% (5y) |
- |
Chipponi et al.(1414. Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, Jaeck D, Fagniez PL, Gainant A. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg. 2004;187:440-5.)
|
205 |
LFC |
39% vs 39% (5y) |
- |
- |
- |
Popiela et al.(4949. Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer. 2004;7:240-5.)
|
156 |
FAM |
30% vs 15,2% (10y) |
0,82 (0,65 – 1,01) |
- |
- |
Bouché et al.(99. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P; Fédération Francophone de Cancérologie Digestive Group. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16:1488-97.)
|
260 |
CF |
46.6% vs 41.9% (5y) |
0,74 (0.54 – 1.02) |
47.6% vs 39.8% (5y) |
0.70 (0.51 – 0.97) |
Nitti et al.(4242. Nitti D, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, Tres A, Coombes RC, Crivellari D, Marchet A, Sanchez E, Bliss JM, Homewood J, Couvreur ML, Hall E, Baron B, Woods E, Emson M, Van Cutsem E, Lise M, EORTC GI Group; ICCG. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006;17:262-9.)
|
397 |
FAMTX or FEMTX |
43% vs 44% (5y) |
0.98 (0.72 – 1.24) |
41% vs 42% (5y) |
0.98 (0.72 – 1.24) |
De Vita et al.(1818. De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol. 2007;18 Suppl 6:vi120-3.)
|
228 |
ELFE |
48% vs 43.5% (5y) |
0.91 (0.69 – 1,21) |
44% vs 39% (5y) |
0.88 (0.78 – 0.91) |
Nakajima et al.(4040. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M, Ohashi Y and Group, National Surgical Adjuvant Study of Gastric Cancer. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94:1468-76.)
|
190 |
UFT |
86% vs 73% (5y) |
0.48 (0.26 – 0.89) |
85% vs 68% (5y) |
0.44 (0.25 – 0.79) |
ACTS-GC |
1059 |
S1 |
71.7% vs 61.1% (5y) |
0.66 (0.54 – 0.82) |
65.4% vs 53.1% (5y) |
0.65 (0.53 – 0.79) |
Di Costanzo et al.(1919. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388-98.)
|
258 |
PELF |
47.6% vs 48.7% (5y) |
0.90 (0.64 – 1.26) |
42.3% vs 41.6% (5y) |
0.92 (0.65 – 1.27) |
Kulig et al.(3232. Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T, Dadan J, Drews M, Jeziorski A, Krawczyk M, Starzynska T, Wallner G. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology. 2010;78:54-61.)
|
309 |
EAP |
47% vs 40% (5y) |
0.74 (0.54 – 1.02) |
- |
- |
CLASSIC |
1035 |
XELOX |
83% vs 78% (3y) |
0.72 (0.52 – 1.00) |
74% vs 59% (3y) |
0.56 (0.44 –0.72) |